ConductScience.org, home

Paper52401

Enhanced cell killing by bleomycin and 43 degrees hyperthermia and the inhibition of recovery from potentially lethal damage.

Braun J and 1 other. Cancer Res, 1975. Cited by 131 papers, by iCite.

Cite this record

ConductScience Library. Enhanced cell killing by bleomycin and 43 degrees hyperthermia and the inhibition of recovery from potentially lethal damage. Papers, record 52401. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/52401

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Enhanced cell killing by bleomycin and 43 degrees hyperthermia and the inhibition of recovery from potentially lethal damage.
PubMed
Journal
Cancer Res
PubMed
Year
1975
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
131
iCite
Relative citation ratio, by iCite
4.76
iCite
Revised in PubMed
2014-11-20
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Braun JJ
2Hahn GMG M

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
BleomycinMajor topic
Cells, CulturedMajor topic
Hot TemperatureMajor topic
Animals
Cell Line
Cell Membrane Permeability
Cell Survival
Cricetinae
DNA Repair
Dose-Response Relationship, Drug
In Vitro Techniques
Kinetics
Time Factors

Source PubMed

Download CSV of topics

Cited by21

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 131 citations.

PMIDTitleJournalYearIn PapersSource
39398925Limb salvage using radical combined hyperthermia and radiotherapy for myxofibrosarcoma of the lower leg in an elderly patient.Int Cancer Conf J2024https://conductscience.org/library/papers/39398925PubMed
37748835Regulatory miRNAs in cancer cell recovery from therapy exposure and its implications as a novel therapeutic strategy for preventing disease recurrence.Enzymes2023https://conductscience.org/library/papers/37748835PubMed
35158893Clinical Evidence for Thermometric Parameters to Guide Hyperthermia Treatment.Cancers (Basel)2022https://conductscience.org/library/papers/35158893PubMed
32198424Thermal Analysis of Infrared Irradiation-Assisted Nanosecond-Pulsed Tumor Ablation.Sci Rep2020https://conductscience.org/library/papers/32198424PubMed
27277962Sound waves and antineoplastic drugs: The possibility of an enhanced combined anticancer therapy.J Med Ultrason (2001)2002https://conductscience.org/library/papers/27277962PubMed
26245485Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all.Radiat Oncol2015https://conductscience.org/library/papers/26245485PubMed
23814202Bleomycin-induced flagellate dermatitis.BMJ Case Rep2013https://conductscience.org/library/papers/23814202PubMed
6208924Inhibition of the recovery from potentially lethal damage by lonidamine.Br J Cancer1984https://conductscience.org/library/papers/6208924PubMed
6205204Enhanced antitumor effects of bleomycin and moderate hyperthermia by additional use of ethanol.Jpn J Surg1984https://conductscience.org/library/papers/6205204PubMed
6199035New type of recovery in HeLa cells exposed to bleomycin.Br J Cancer1984https://conductscience.org/library/papers/6199035PubMed
6193307Hyperthermo-chemo-radiotherapy for carcinoma of the esophagus.Jpn J Surg1983https://conductscience.org/library/papers/6193307PubMed
3404776Experimental studies of the effects of local hyperthermia on blood flow, oxygen pressure and pH in tumors.Jpn J Surg1988https://conductscience.org/library/papers/3404776PubMed
3006735Changes in the response of the RIF-1 tumour to melphalan in vivo induced by inhibitors of nuclear ADP-ribosyl transferase.Br J Cancer1986https://conductscience.org/library/papers/3006735PubMed
2418860Interaction of bleomycin, hyperthermia and a calmodulin inhibitor (trifluoperazine) in mouse tumour cells: I. In vitro cytotoxicity.Br J Cancer1986https://conductscience.org/library/papers/2418860PubMed
2418859Interaction of bleomycin, hyperthermia and a calmodulin inhibitor (trifluoperazine) in mouse tumour cells: II. DNA damage, repair and chromatin changes.Br J Cancer1986https://conductscience.org/library/papers/2418859PubMed
2411985Radiation-induced esophageal carcinoma responded well to hyperthermic chemotherapy--a case report.Jpn J Surg1985https://conductscience.org/library/papers/2411985PubMed
2409315Synergistic effect of K-18 and concomitant hyperthermia for treatment of Lewis lung carcinoma in mice.Jpn J Surg1985https://conductscience.org/library/papers/2409315PubMed
1707464A new experimental trial using repeated heating every 24 hours for local hyperthermic therapy with bleomycin in vivo.Jpn J Surg1990https://conductscience.org/library/papers/1707464PubMed
137590The effect of hyperthermia on DNA repair.Z Krebsforsch Klin Onkol Cancer Res Clin Oncol1976https://conductscience.org/library/papers/137590PubMed
87213The interaction of thermal tolerance with drug cytotoxicity in vitro.Br J Cancer1979https://conductscience.org/library/papers/87213PubMed

See all 21 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/52401

GET https://conductscience.org/api/papers/v1/52401/cited_by?page=2